RA0133

antibody from Oursmab

Targeting: CD8A CD8

ELISA (Recommended by provider)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0133

Provider

Oursmab

Product name

Crefmirlimab (Biosimilar Reference Antibody) (CD8A)

Antibody type

Monoclonal

Description

Crefmirlimab is an investigational humanized mini-antibody or antibody fragment engineered for specificity toward CD8. This design implies a focus on modulating the function or activity of CD8+ T cells, a critical population of cytotoxic lymphocytes in the immune system. Such a molecule is likely being developed as an immunomodulatory therapy, potentially for applications in oncology (e.g., to enhance anti-tumor T-cell responses) or in autoimmune diseases (e.g., to selectively deplete or inhibit pathogenic CD8+ T cells). Its "mini-antibody" format may offer advantages in tissue penetration and pharmacokinetics compared to full-length antibodies.

Reactivity

Human

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.